Combined Rituximab + Omalizumab Promising for Refractory BP Combined Rituximab + Omalizumab Promising for Refractory BP
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration –approved therapies for BP exist.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Dermatology Source Type: news
More News: Cancer & Oncology | Dermatology | Food and Drug Administration (FDA) | Hematology | Pemphigoid | Rituxan | Skin | Xolair